Neuroprotection under pressure: rethinking hyperbaric oxygen therapy

Rafael Franco , Christopher A. Shaw , Andrew Paterson

Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) : 1004157

PDF (3117KB)
Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) :1004157 DOI: 10.37349/ent.2026.1004157
Perspective
research-article
Neuroprotection under pressure: rethinking hyperbaric oxygen therapy
Author information +
History +
PDF (3117KB)

Abstract

This Perspective explores why hyperbaric oxygen therapy (HBOT) deserves closer clinical and scientific attention as a possible treatment for ischemic stroke and a potential neuroprotective strategy in chronic central nervous system disorders, especially multiple sclerosis and other progressive or age-related neurological conditions. While HBOT is not yet widely accepted for these indications, three factors justify reconsideration: its strong safety profile, a biologically plausible mechanistic rationale, and recurrent signals of benefit from selected neurological studies. We review HBOT’s historical development, current accepted indications, and evidence that adverse effects are generally mild, uncommon, and reversible under modern protocols. In neurology, efficacy remains unproven, yet interest persists due to preliminary findings and repeated patient-reported improvements. A central argument is that the main barrier to progress is not safety, but evidence generation. Conventional randomized controlled trials face major challenges: difficult blinding, wide variation in dosing protocols, and uncertainty about meaningful outcomes in chronic neurological disease. Moreover, HBOT is non-patentable, which limits commercial investment and leaves a potentially valuable intervention underexplored. Mechanistically, we move beyond explanations centred solely on oxygen delivery or oxidative stress. As a working hypothesis, neurological benefits may partly arise from cumulative adaptive responses-including a rebound hormesis following repeated hyperoxic exposure. We conclude with a pragmatic research agenda: continuous, low-cost physiological monitoring in patients already receiving HBOT, coupled with a medium-term goal of adequately powered efficacy trials.

Keywords

hyperbaric oxygen therapy / neuroprotection / multiple sclerosis / central nervous system disorders / neurodegeneration / oxidative stress / ischemic conditioning / biohacking

Cite this article

Download citation ▾
Rafael Franco, Christopher A. Shaw, Andrew Paterson. Neuroprotection under pressure: rethinking hyperbaric oxygen therapy. Exploration of Neuroprotective Therapy, 2026, 6 (1) : 1004157 DOI:10.37349/ent.2026.1004157

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Mitchell SJ, Bennett MH, Moon RE. Decompression Sickness and Arterial Gas Embolism. N Engl J Med. 2022; 386: 1254-64.

[2]

Gabb G, Robin ED. Hyperbaric oxygen. A therapy in search of diseases. Chest. 1987; 92: 1074-82.

[3]

Ingle R. Hyperbaric oxygen therapy. JAMA. 1990; 264: 1811.

[4]

Grim PS, Gottlieb LJ, Boddie A, Batson E. Hyperbaric oxygen therapy. JAMA. 1990; 263: 2216-20.

[5]

Hadanny A, Meir O, Bechor Y, Fishlev G, Bergan J, Efrati S. The safety of hyperbaric oxygen treatment--retrospective analysis in 2,334 patients. Undersea Hyperb Med. 2016; 43: 113-22.

[6]

Jokinen-Gordon H, Barry RC, Watson B, Covington DS. A Retrospective Analysis of Adverse Events in Hyperbaric Oxygen Therapy (2012-2015): Lessons Learned From 1.5 Million Treatments. Adv Skin Wound Care. 2017; 30: 125-9.

[7]

Zhang Y, Zhou Y, Jia Y, Wang T, Meng D. Adverse effects of hyperbaric oxygen therapy: a systematic review and meta-analysis. Front Med (Lausanne). 2023; 10: 1160774.

[8]

Brenna CTA, Khan S, Djaiani G, Au D, Schiavo S, Wahaj M, et al. Pulmonary function following hyperbaric oxygen therapy: A longitudinal observational study. PLoS One. 2023; 18: e0285830.

[9]

Tibbles PM, Edelsberg JS. Hyperbaric-oxygen therapy. N Engl J Med. 1996; 334: 1642-8.

[10]

Indications for Hyperbaric Oxygen Therapy [Internet]. [cited 2026 Apr 6]. Available from: https://www.uhms.org/resources/featured-resources/hbo-indications.html

[11]

Hadanny A, Rittblat M, Bitterman M, May-Raz I, Suzin G, Boussi-Gross R, et al. Hyperbaric oxygen therapy improves neurocognitive functions of post-stroke patients - a retrospective analysis. Restor Neurol Neurosci. 2020; 38: 93-107.

[12]

Boussi-Gross R, Golan H, Volkov O, Bechor Y, Hoofien D, Beeri MS, et al. Improvement of memory impairments in poststroke patients by hyperbaric oxygen therapy. Neuropsychology. 2015; 29: 610-21.

[13]

Boussi-Gross R, Golan H, Fishlev G, Bechor Y, Volkov O, Bergan J, et al. Hyperbaric oxygen therapy can improve post concussion syndrome years after mild traumatic brain injury - randomized prospective trial. PLoS One. 2013; 8: e79995.

[14]

Harch PG. Systematic Review and Dosage Analysis: Hyperbaric Oxygen Therapy Efficacy in Mild Traumatic Brain Injury Persistent Postconcussion Syndrome. Front Neurol. 2022; 13: 815056.

[15]

Zhang Z, Zhang W, Xu Y, Liu D. Efficacy of hyperbaric oxygen therapy for diabetic foot ulcers: An updated systematic review and meta-analysis. Asian J Surg. 2022; 45: 68-78.

[16]

Huang ET, Mansouri J, Murad MH, Joseph WS, Strauss MB, Tettelbach W, et al.; UHMS CPG Oversight Committee. A clinical practice guideline for the use of hyperbaric oxygen therapy in the treatment of diabetic foot ulcers. Undersea Hyperb Med. 2015; 42: 205-47.

[17]

Santema KTB, Stoekenbroek RM, Koelemay MJW, Reekers JA, van Dortmont LMC, Oomen A, et al.; DAMO2CLES Study Group. Hyperbaric Oxygen Therapy in the Treatment of Ischemic Lower-Extremity Ulcers in Patients With Diabetes: Results of the DAMO2CLES Multicenter Randomized Clinical Trial. Diabetes Care. 2018; 41: 112-9.

[18]

McIntosh SE, Freer L, Grissom CK, Auerbach PS, Rodway GW, Cochran A, et al. Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Frostbite: 2019 Update. Wilderness Environ Med. 2019; 30: S19-32.

[19]

Magnan MA, Gayet-Ageron A, Louge P, Champly F, Joffre T, Lovis C, et al. Hyperbaric Oxygen Therapy with Iloprost Improves Digit Salvage in Severe Frostbite Compared to Iloprost Alone. Medicina (Kaunas). 2021; 57: 1284.

[20]

Magnan DM, Gelsomino M, Louge P, Pignel R. Successful Delayed Hyperbaric Oxygen Therapy and Iloprost Treatment on Severe Frostbite at High Altitude. High Alt Med Biol. 2022; 23: 294-7.

[21]

Mensah-Kane P, Sumien N. The potential of hyperbaric oxygen as a therapy for neurodegenerative diseases. Geroscience. 2023; 45: 747-56.

[22]

Hadanny A, Daniel-Kotovsky M, Suzin G, Boussi-Gross R, Catalogna M, Dagan K, et al. Cognitive enhancement of healthy older adults using hyperbaric oxygen: a randomized controlled trial. Aging (Albany NY). 2020; 12: 13740-61.

[23]

Steele J, Matos LA, Lopez EA, Perez-Pinzon MA, Prado R, Busto R, et al. A Phase I safety study of hyperbaric oxygen therapy for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004; 5: 250-4.

[24]

Steele J, Zutshi D, Bradley WG. Negative results of a phase II study of hyperbaric oxygen therapy for amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2007; 8: 274-5.

[25]

Fischer BH, Marks M, Reich T. Hyperbaric-oxygen treatment of multiple sclerosis. A randomized, placebo-controlled, double-blind study. N Engl J Med. 1983; 308: 181-6.

[26]

Neubauer RA, Barnes MP, Bates D, Cartlidge NEF, French JM, Shaw DA, et al. Hyperbaric oxygen for multiple sclerosis. Lancet. 1985; 325: 810-1.

[27]

James PB. Hyperbaric oxygen and multiple sclerosis. J Neurol Neurosurg Psychiatry. 1988; 51: 887-9.

[28]

Bennett M, Heard R. Hyperbaric oxygen therapy for multiple sclerosis. CNS Neurosci Ther. 2010; 16: 115-24.

[29]

Murray TJ. The History of Diagnosis and Treatment of MS: a Brief Overview. Curr Neurol Neurosci Rep. 2022; 22: 545-9.

[30]

Schottlender N, Gottfried I, Ashery U. Hyperbaric Oxygen Treatment: Effects on Mitochondrial Function and Oxidative Stress. Biomolecules. 2021; 11: 1827.

[31]

Cannellotto M, Yasells García A, Landa MS. Hyperoxia: Effective Mechanism of Hyperbaric Treatment at Mild-Pressure. Int J Mol Sci. 2024; 25: 777.

[32]

James PB. Oxygen and the Brain: The Journey of Our Lifetime. Best Publishing Company; 2017.

[33]

Franco R, Serrano-Marín J. Can chronic therapeutic drug use by the elderly affect Alzheimer’s disease risk and rate of progression? Explor Neuroprot Ther. 2023; 3: 8-23.

[34]

Volonté C, Hu G, Shaw CA, Viegas C, dos Santos JA, Vaz SH, et al. Neuroprotection beyond neurons: integrated biomarker-based and astroglia- or microglia-targeted approaches to combat neurodegenerative diseases. Explor Neuroprot Ther. 2026; 6: 1004136.

[35]

Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986; 74: 1124-36.

[36]

Liu L, Sun XY, Cui C, Liu M, Cui Y, Chen HS. The efficacy of remote ischemic conditioning for outcomes in ischemic stroke patients with or without prior stroke: A post hoc analysis of the RICAMIS trial. Eur J Neurol. 2025; 32: e70032.

[37]

Ganesh A, Gaist D, Modrau B, Gude MF, Behrndtz AB, Andersen G, et al. Pre-hospital treatment duration and efficacy of remote ischaemic conditioning in the RESIST randomised-controlled trial. Eur Stroke J. 2026; 11: aakaf015.

[38]

Qiao Y, Hui W, Li S, Ding Y, Ji X, Zhao W. Remote ischaemic conditioning for preventing and treating ischaemic stroke. Cochrane Database Syst Rev. 2025; 9: CD012503.

[39]

Cai L, Ding Y, Tekreeti AA, Li F, Zhu Y, Geng X, et al. Remote ischemic conditioning as a potential therapy for Parkinson’s Disease: Inhibiting TLR4-Driven neuroinflammation and oxidative damage. Brain Res. 2025; 1866: 149920.

[40]

Hadanny A, Efrati S. The Hyperoxic-Hypoxic Paradox. Biomolecules. 2020; 10: 958.

[41]

Harch PG, Rhodes S. Acute and chronic central nervous system oxidative stress/toxicity during hyperbaric oxygen treatment of subacute and chronic neurological conditions. Front Neurol. 2024; 15: 1341562.

[42]

Paganini M, Moon RE, Boccalon N, Melloni GEM, Giacon TA, Camporesi EM, et al. Blood gas analyses in hyperbaric and underwater environments: a systematic review. J Appl Physiol (1985). 2022; 132: 283-93.

[43]

Godman CA, Joshi R, Giardina C, Perdrizet G, Hightower LE. Hyperbaric oxygen treatment induces antioxidant gene expression. Ann N Y Acad Sci. 2010; 1197: 178-83.

[44]

Gehr S, Kaiser T, Kreutz R, Ludwig WD, Paul F. Suggestions for improving the design of clinical trials in multiple sclerosis-results of a systematic analysis of completed phase III trials. EPMA J. 2019; 10: 425-36.

[45]

Marrie RA, Miller A, Sormani MP, Thompson A, Waubant E, Trojano M, et al.; attendees of the International Workshop on Comorbidity in Multiple Sclerosis. The challenge of comorbidity in clinical trials for multiple sclerosis. Neurology. 2016; 86: 1437-45.

[46]

Nosengo N. Can you teach old drugs new tricks? Nature. 2016; 534: 314-6.

[47]

Breckenridge A, Jacob R. Overcoming the legal and regulatory barriers to drug repurposing. Nat Rev Drug Discov. 2019; 18: 1-2.

[48]

Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019; 18: 41-58.

PDF (3117KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉